Congratulations to Isofol Medical AB (publ) on the first patient inclusion in the phase Ib/II study of arfolitixorin. LINK Medical is Isofol’s primary CRO that manages the clinical study on behalf of and in collaboration with Isofol.
We are proud to support the advancement of new treatment options for metastatic colorectal cancer. A special thank you to Malin Olsen, CPM at LINK Medical, and her team for their diligent work in bringing the study successfully to activation. We look forward to continuing the collaboration with Isofol and Charité – Universitätsmedizin Berlin.
